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The development of a successful vaccine against HIV is likely to require the induction of
strong and long-lasting humoral immune responses at the mucosal portal of virus entry.
Hence, the design of a vaccine strategy able to induce mucosal antibodies and in particular
speciﬁc IgA, may be crucial to providing immune protection. Nasal immunisation is
known to induce speciﬁc IgG and IgA responses in the cervicovaginal mucosa; however,
there is an urgent need for the development of safe, effective and accessible mucosal
adjuvants for nasal application in humans. To reduce the potential for adverse events
associated with some nasal adjuvants, we have assessed whether the B-cell-activating
cytokines APRIL, BAFF and TSLP enhance humoral immune responses to HIV-1 gp140.
Following intranasal immunisation, TSLP but not APRIL or BAFF induced strong humoral
responses both in serum and mucosa. The adjuvant effect of TSLP on humoral responses
was similar to that of cholera toxin (CT). The use of TSLP as an adjuvant skewed both the
cellular and humoral immune responses towards Th2 cells. This is the ﬁrst time that TSLP
has been demonstrated to have a positive effect as a mucosal adjuvant, and speciﬁcally to
promote mucosal and systemic responses to HIV gp140.
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Introduction
The predominant route of sexual HIV transmission to women is
via the mucosa of the genitourinary tract. For this reason, there is
a growing consensus that a vaccine is needed that can induce
both cellular and humoral immunity in systemic and mucosal
compartments [1]. While research has focused on the induction
of systemic CTL responses and neutralising antibodies, the
induction of IgA at mucosal surfaces by vaccination has received
less attention. This may provide alternative or additional
protective function to the classical antibody neutralisation. In
particular, mucosal IgA is: predominantly dimeric; more resistant
to protease degradation than IgG isotypes; can aggregate and/or
trap virus in cervical mucus, limiting direct contact with the
underlying epithelium; is speciﬁcally secreted at mucosal surfaces
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(pIgR) on columnar epithelial cells, can prevent epithelial
transcytosis; and, where neutralising antibodies are induced,
can facilitate intraepithelial cell neutralisation [2]. As there are
currently major challenges in the induction of broadly neutralis-
ing antibodies to HIV-1, it is thought that such immune exclusion
functions of speciﬁc IgA could be exploited in a mucosal vaccine
to augment conventional IgG neutralisation.
Nasal immunisation has long been reported as one of the most
effective routes to induce immune responses in the female genital
tract [3]. It is easily accessible, may be more culturally accepted than
the vaginal or rectal routes of immunisation, requires lower amounts
of antigen to induce immune response, and has the ability to induce
potent responses both in serum and mucosally [4]. However, the
magnitude of the immune response depends, to some extent, on
immunogen, adjuvant, and delivery method [5]. Currently, there is
an important need for the development of safe and effective adju-
vants for nasal application in humans. Due to inherent safety issues,
cholera toxin (CT), the model mucosal adjuvant used for many
animal studies, is not appropriate for human use, and detoxiﬁed
versions of CT and the closely related heat-labile enterotoxins (LTs)
from Escherichia coli also have safety concerns for intranasal use in
humans [6]. While studies have shown that a range of other adju-
vants can promote intranasal immunisation with HIV envelope
proteins (gp120, gp140 and gp160) in animal models [7–13], many
of these adjuvants trigger multiple signalling pathways, which may
not be central to their adjuvant effects, increasing the potential for
unwanted side effects in humans. Furthermore, not only are
mucosal responses per se often short-lived, antibody responses to
HIV envelope proteins can rapidly wane in the systemic compart-
ment after each immunisation [14–16]. This only serves to highlight
the pressing need to develop novel mucosal adjuvant strategies for
HIV-1 envelope based vaccines.
A possible alternative approach to the induction of potent and
enduring mucosal responses to HIV envelope proteins is the use
of speciﬁc B-cell-associated cytokines such as thymic stromal
lymphopoietin (TSLP), a proliferation-inducing ligand (APRIL)
and B-cell-activating factor (BAFF), which are strong inducers of
humoral responses [17]. These may be potentially safer as they
could directly target B cells and/or DCs without activating other
redundant pathways, unlike the more pleiotropic effects of other
adjuvants. TSLP is an IL-7-like 4-helix bundle cytokine of 140-
amino acids that was originally shown to support B-cell devel-
opment [18, 19]. The induction of TSLP in mice is associated with
several known TLR ligands (e.g. Poly I:C) and proinﬂammatory
cytokines (e.g. IL-1a/b and TNF-a) [20]. TSLP activates DCs, but
also provides DCs with the ability to create a permissive envir-
onment for TH2 cell differentiation [21], which may promote the
generation of antigen-speciﬁc IgA-producing B cells. This may be
mediated in part through the induction of BAFF and APRIL
augmenting class switching by intraepithelial B cells [20, 22].
BAFF and APRIL are members of the TNF ligand superfamily.
BAFF, and possibly APRIL, have been shown to be crucial factors
involved in class switch recombination from Cm to Cg and/or Ca,
with subsequent increase of IgG- and IgA-secreting cells, respec-
tively [23]. However, the use of such factors as adjuvants is not
clear-cut. TSLP has been associated with allergy, particularly
relating to the induction of IgE [24], while the induction of BAFF
by gp120 binding to C-type lectin receptors has been proposed as
a mechanism for polyclonal immunoglobulin class switching
through a CD4
1 T-cell-independent mechanisms [25].
In this study, we have investigated whether TSLP, APRIL and
BAFF can be used as effective intranasal adjuvants for HIV-1
gp140. TSLP but not APRIL or BAFF induced strong and sustained
serum and mucosal immune responses after nasal immunisation,
comparable to those seen with CT. Intranasal, but not intra-
dermal immunisation induced vaginal IgA responses, while both
routes induced systemic IgG. Of note TSLP shifted the immune
response towards a Th2-type response. These results suggest that
TSLP may be a promising new intranasal adjuvant to enhance
immune responses to gp140 and other nasal vaccines.
Results
TSLP induces speciﬁc immune responses after intra-
nasal immunisation
We initially explored the potential of TSLP, APRIL, BAFF as
mucosal vaccine adjuvants. Mice were immunised i.n. or intra-
dermally (i.d.) three times at 3 week intervals in a prime-boost-
boost protocol with 10mg CN54gp140 alone or in the presence of
5mg TSLP, APRIL or BAFF. Anti-gp140-reactive IgG and IgA were
measured in serum and vaginal lavage collected at the end of the
experiment. Mice immunised i.n. with gp140 plus TSLP but not
APRIL or BAFF induced high titres of gp140-speciﬁc IgA and IgG in
serum and vaginal lavage (Fig. 1A–D). Neither TSLP, APRIL nor
BAFF had any adjuvant effect compared to gp140 alone when used
i.d. (data not shown). Bioactivity of the APRIL and BAFF used was
conﬁrmed using a B-cell proliferation assay (data not shown).
The adjuvant effect of i.n. TSLP was dose dependent with
maximal responses seen at 5mg (data not shown). TSLP induced
signiﬁcantly higher systemic and vaginal responses to intranasal
immunisation with ovalbumin (OVA) compared with OVA alone
(data not shown) demonstrating that the adjuvant potential of
TSLP was not antigen speciﬁc.
No side effects were observed during or after the administration
of any of the immunisations (data not shown). We wished to
determine whether intranasal TSLP was inducing an acute inﬂam-
matory response. Mice were i.n. immunised with CN54 gp140 alone
or with CT or TSLP, i.n. LPS and PBS were used as controls. Six
hours later mice were culled and cells from the bronchoalveolar
lavage (BAL) recovered. There was no signiﬁcant difference in cell
recovery between groups (data not shown). While i.n. LPS exposure
induced a signiﬁcant recruitment of neutrophils, there was no
difference between gp140:TSLP, gp140:CT or gp140 alone
compared with the PBS controls (data not shown), with the BAL
predominantly composed of macrophages. There were no observable
differences in lung or nasal sections stained with either H&E or
Periodic acid-Schiff (PAS).
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cellular response to gp140 is comparable to that of CT
Having demonstrated that TSLP was the most effective cytokine
adjuvant of those tested, we sought to compare it with CT a
mucosal adjuvant commonly used in murine studies [3, 5]. Mice
were immunised three times i.n. with 10mg gp140 alone or
with 5mg TSLP or CT. The strong humoral immune responses to
gp140 induced by TSLP in serum and mucosally, vaginal lavage
and faeces, was comparable to that observed with CT (Fig. 2).
CN54 gp140-speciﬁc IgA and IgG antibody-secreting cells (ASC)
were detected by ELISPOT in the spleen of animals immunised
with gp140 plus TSLP or CT (Fig. 2G). Splenocytes were isolated
and cultured with CN54 gp140 protein or a selected CN54 gp140
peptide pool. T-cell proliferation was measured by
3H thymidine
incorporation. CT induced signiﬁcantly more T-cell proliferation
to both the protein (Fig. 2H) than antigen alone or TSLP. Both
antigen alone and TSLP induced some cell proliferation.
Immunisation with TSLP induces a Th2-skewed
immune response
TSLP has been associated with a shift in the immune response
towards Th2-type responses [26]. Mice were immunised three
Figure 1. TSLP induces gp140-speciﬁc immune responses after intra-
nasal immunisation. Mice were immunised with 10mg gp140 in the
presence or absence of 5mg TSLP, APRIL or BAFF i.n. three times at
3 week intervals. Anti-gp140 IgA (left) and IgG (right) were measured
3 weeks after the ﬁnal immunisation by ELISA in (A) serum and
(B) vaginal lavage. Data are shown as endpoint titres, with lines
representing geometric means of n55 mice; data are representative of
two experiments. po0.05, po0.01, po0.001, one-way analysis of
variance (ANOVA) with Tukey’s multiple comparison post test.
Figure 2. TSLP induces similar humoral but not cellular responses to
CT. Mice were immunised three times i.n. with 10mg gp140 alone
(1),with 5mg TSLP (W)o rC T( B). Anti-gp140 IgA and IgG were
measured by ELISA in (A, B) serum, (C, D) vaginal lavage and (E, F)
faecal extracts obtained from mice 3 weeks after the ﬁnal immunisa-
tion. (G) Anti-gp140 IgA and IgG ASC were measured by B-cell ELISPOT
in spleen from mice 3 wks after the ﬁnal immunisation. (H) 10 days
after the ﬁnal immunisation, splenocytes were isolated and cultured
for 5 days with CN54 gp140 protein and proliferation measured by
3H thymidine incorporation. Data points represent single mice, bars
represent mean of n55 mice1SD (G, H). Data are representative of two
experiments. po0.05, po0.01, po0.001, one-way analysis of
variance (ANOVA) with Tukey’s multiple comparison post test.
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The use of TSLP as an adjuvant induced a shift in the gp140-
speciﬁc IgG subtype response towards IgG1, which is asso-
ciated with Th2-cell responses, compared to CT (Fig. 3A). Both
TSLP and CT led to a small, but not statistically signiﬁcant, level
of gp140-speciﬁc IgE detectable following three immunisation
(Fig. 3B). We measured intra-cellular cytokine expression to a
CN54 peptide pool in both CD4
1 and CD8
1 T cells (sample plots
in Supporting Information Fig. 1). Antigen alone, TSLP plus
antigen and CT plus antigen all induced signiﬁcant levels of
gp140-speciﬁc IL-2 production in both CD4
1 and CD8
1 T cells
and IL-4 in CD4 cells. CT plus antigen also induced signiﬁ-
cant levels of TNF, IFN-g and IL-17 expression by CD4
1 T cells
(Fig. 3C).
To further characterise the Th2-cell skewing of immune
responses following immunisation with TSLP plus gp140, we
adapted a model of allergic airway disease. It has been previously
shown that immunisation of mice with antigen (normally oval-
bumin) and alum i.p. can induce a strongly pro-Th2-cell
response, with IgE, airway eosinophilia and goblet cell hyper-
plasia. We therefore used i.p. gp140 and alum as a positive
control compared to i.n. immunisation with PBS, CN54 gp140
alone or with CT or TSLP. Mice were i.n. immunised (using a
20mL volume) twice, at 2 week intervals, followed by an
exacerbated airway challenge of three i.n. doses of 20mg gp140
alone (in a 100-mL volume to maximise airway exposure) and
subsequently culled 3 days later (Fig. 3D).
Following challenge, mice immunised with gp140 and an
adjuvant had signiﬁcantly higher production of gp140-speciﬁc
IgE than mice immunised with gp140 alone. Levels of IgE were
signiﬁcantly higher in mice immunised with gp140:alum than
gp140:TSLP or gp140:CT (Fig. 3E). Mice immunised with gp140
plus adjuvant had a greater total cell recruitment to the airway
than mice immunised with PBS or gp140 alone (Fig. 3F). The
BAL of mice immunised with PBS or gp140 alone was predomi-
nantly comprised macrophages (Fig. 3G). There were signiﬁ-
cantly more lymphocytes recruited to the airways of mice
immunised with adjuvant (regardless of adjuvant). Mice immu-
nised with gp140:CT had a signiﬁcant neutrophilia compared to
all other groups. Mice immunised with gp140:TSLP or
gp140:alum had signiﬁcantly more eosinophilia than the other
groups. Staining of lung sections with PAS showed that immu-
nisation with PBS (Fig. 3H) or gp140 (Fig. 3I) alone did not lead
to the development of goblet cell metaplasia around the major
airways. However, the use of an adjuvant led to a goblet cells
metaplasia and mucous production (pink-stained cells). Similar
PAS-stained cells were detected in the gp140:TSLP (Fig. 3J) and
gp140:alum (Fig. 3L) groups, with slightly less staining in the
gp140:CT (Fig. 3K) group. Immunisation with gp140:CT led to a
greater inﬁltration around blood vessels and large proximal
airways than in other groups, using H&E staining it was seen
that this inﬁltrate had a larger proportion of granulocytes than
other groups. From all of these data, it can be concluded that
TSLP does skew the immune response towards a Th2-cell-type
response.
I.n. immunisation induces higher gp140-speciﬁc
IgA responses, but not IgG, than intradermal
immunisation
To compare the effect of route of immunisation on the kinetics
and distribution of the antibody responses, mice were immunised
i.n. or i.d. with gp140 and adjuvants. Intradermal immunisation
induced gp140-speciﬁc serum IgG responses earlier than i.n.
immunisation with signiﬁcant seroconversion after the ﬁrst
immunisation (Fig. 4A). Serum anti-gp140 IgG titres reached
similar levels after the second immunisation regardless of the
route (Fig. 4A). In contrast to IgG, i.n. immunisation induced
gp140-speciﬁc serum IgA responses more rapidly than i.d.
immunisation and led to signiﬁcantly higher values (po0.001,
Fig. 4B). In vaginal lavage and faecal extracts, similar levels of
speciﬁc gp140 IgG were observed after immunisation by either
route (Fig. 4C). However, only i.n. immunisation induced high
titres of speciﬁc gp140 IgA in mucosal samples (Fig. 4D). No IgG
was detectable in nasal lavage, but gp140-speciﬁc IgA was
detected after i.n. immunisation.
TSLP induces durable humoral and cellular responses
to intranasal immunisation with gp140
To investigate whether the responses to gp140 induced by TSLP
were durable, mice were immunised i.n. three times at 3 weeks
intervals and then given a fourth immunisation 6 months later.
Serum speciﬁc IgA and IgG levels were sustained for 6 months
after the third immunisation and there was minimal impact of a
fourth immunisation (Fig. 5A and B). Speciﬁc IgA and IgG levels
in vaginal lavage of animals immunised i.n. with gp140 plus TSLP
appeared to decrease slightly in the course of 6 months, but this
trend was only signiﬁcant for IgG with TSLP (po0.05). Boosting
at 6 months restored these responses to levels seen after the third
boost at day 63 (Fig. 5C and D).
Spleens were collected after the ﬁnal immunisation, and
gp140-speciﬁc IgA and IgG B-cell ELISPOT assays were performed.
gp140-speciﬁc IgA- and IgG-ASC were induced in the spleen after
i.n. immunisation (Fig. 5E). TSLP and CT signiﬁcantly induced
splenocyte T-cell proliferation responses to gp140 (Fig. 5G), but
CT responses were greater than TSLP. Both adjuvants induced
CD4
1 and CD8
1 T-cell proliferation measured by CFSE (Fig. 5H).
Discussion
This study assessed the capacity of the B-cell-activating cytokines
APRIL, BAFF and TSLP to enhance humoral and cellular immune
responses to HIV-gp140 after intranasal immunisation. TSLP, but
not APRIL or BAFF, was able to induce strong, long-lasting
antibody responses both in serum and mucosally, including the
vaginal compartment. These responses were comparable to those
induced by the established experimental mucosal adjuvant CT. In
addition, intranasal immunisation induced higher gp140-speciﬁc
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mising levels of speciﬁc IgG levels in serum. IgA and IgG
producing gp140-speciﬁc B cells were detected in the spleen.
TSLP also induced T-cell responses to gp140, with speciﬁc CD4
1
T-cell responses greater than CD8
1 T-cell responses.
Although the previous studies have shown that systemic
responses to HIV envelope protein (Env) rapidly wane in humans
after each immunisation [14–16], TSLP induced sustained
systemic IgG and IgA responses in mice that showed no diminu-
tion over a six-month period. Furthermore, while mucosal
Figure 3. TSLP shifts the immune response to gp140 to Th2 Mice were immunised three times i.n. with 10mg gp140 alone or with 5mg TSLP or CT.
(A) Anti-gp140 IgG1 and IgG2a and (B) IgE were measured in serum by ELISA. (C) Splenocytes were stimulated with a CN54 gp140 peptide pool and
speciﬁc cytokine production was measured in CD4
1 T cells by ﬂow cytometry. (D) Mice were immunised twice at 2 week intervals, followed by
three daily i.n. challenges with 20mg gp140 in 100mL and were culled 3 days later. (E) gp140-speciﬁc IgE was measured in sera. (F) Cells were
collected from bronchoalveolar lavage (BAL) and counted and (G) differential cell counts performed. Representative PAS-stained sections of lungs
from (H) PBS, (I) gp140, (J) gp140:TSLP, (K) gp140:CT, (L) IP gp140:alum. Data are shown as mean of n55 mice1SD, experiment performed once.
po0.05, po0.01, po0.001, one-way analysis of variance (ANOVA) with Tukey’s multiple comparison post test.
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over this period, these were restored following a booster
immunisation at six months. It is unclear whether these results
will directly translate to humans, nevertheless the observed
duration of humoral response is encouraging. As the main focus
of this study was to determine the impact of routes of admin-
istration on speciﬁc humoral responses, we did not assess
neutralisation responses. This has however been previously
characterised for the CN54 gp140 in rabbits [27], thought to be a
more appropriate model than mice for assessment of neutralisa-
tion breadth.
The speciﬁc mechanisms underlying the adjuvant affect of
TSLP on the immune response to gp140 have not been deﬁned,
but based on its known properties we speculate that TSLP may
directly activate DCs situated within the nasal mucosa to take
up antigen via dendrites that protrude the nasal epithelium
[28]. TSLP licensed DCs could then activate T-helper cells
inducing B-cell activation and differentiation [21, 29–31] or act
directly on B cells by producing BAFF and/or APRIL [22, 23,
32]. TSLP has been shown to boost DC priming of CD8
1 Tc e l l s
following BCG exposure in vitro [33]. Epithelial cells [34],
basophils [35] and M cells may also potentiate the adjuvant
action of TSLP.
In addition, TSLP, in combination with TCR stimulation, can
act directly on naı ¨ve CD4
1 T cells to promote Th2-cell differ-
entiation [36, 37], proliferation and survival of effecter Th2 cells
[38]. Supporting this mechanism, we observed a Th2 bias in the
cellular and Ig response to gp140 when delivered with TSLP. The
Th2 skewing of antigen-speciﬁc responses induced by TSLP may
be a possible safety concern for further development of TSLP as
an adjuvant. The observation that TSLP could induce eosinophilia
in a model of allergy airway disease is consistent with previous
studies demonstrating that i.n. immunisation every other day for
2 weeks using 0.5mg TSLP plus OVA induced allergic airway
disease [39]. It is unclear as to the physiological relevance of such
chronic exposure to discrete immunisations. Indeed, using a
Figure 4. I.n. immunisation induces higher gp140-speciﬁc IgA responses than i.d immunisation. Mice were immunised i.n. (open symbols) or i.d.
(black symbols) three times with 10mg gp140 alone or with 5mg TSLP or CT. (A, C) Anti-gp140 IgG and (B, D) anti-gp140 IgAwere measured by ELISA
(A, B) in serum 3 weeks after priming (ﬁrst immunisation), ﬁrst boost (second immunisation) and ﬁnal immunisation (third immunisation) and (C,
D) in vaginal lavage, faecal extracts and nasal lavage 3 weeks after the ﬁnal immunisation. Data are shown as endpoint titres, with lines
representing geometric means of n55 mice; data are representative of two experiments. po0.001, one-way analysis of variance (ANOVA) with
Tukey’s multiple comparison post test.
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was no signiﬁcant antigen-speciﬁc IgE production compared to
antigen alone or CT and the absolute amount of speciﬁc IgE was
considerably less than speciﬁc IgG or IgA. Furthermore, a single
immunisation with TSLP and antigen failed to induce goblet cell
metaplasia or acute inﬁltration in the airways.
The induction of antigen-speciﬁc T cells by TSLP is a critical
step in the induction of a strong antibody response and may
account for the difference in the adjuvant activity observed
between TSLP and BAFF/APRIL. Thus, whereas TSLP acts upon
DCs and T cells to induce a stronger Th2 phenotype
[21, 37], BAFF and APRIL act directly on B cells promoting T-cell-
independent responses [40]. The observed lack of response to
APRIL alone contrasts with a previous study suggesting that
APRIL enhanced i.n. immunisation with OVA in BALB/c mice [7],
however this former study utilised human APRIL in the mouse
model, shown to bind murine receptors BCMA and TACI [41],
and therefore direct comparisons cannot be made.
Importantly, the adjuvant effect of TSLP described here does
not appear to be antigen speciﬁc as it was also observed to
enhance immune response to i.n. immunisation with OVA (data
not shown). Such data suggest the adjuvant properties of TSLP
may be broadly applicable. We also evaluated the ability of TSLP
to induce speciﬁc responses by additional mucosal routes. Inter-
estingly, whereas sublingual immunisation-induced responses
were almost as potent as intranasal immunisation (data not
Figure 5. TSLP induces sustained humoral and cellular immune responses to gp140. Mice were immunised four times i.n. with 10mg gp140 alone
(&) or with 5mg TSLP (J)o rC T( B). The fourth immunisation was given 6 months after the third immunisation. Anti-gp140 IgA and IgG were
measured by ELISA in (A, B) serum and (C, D) vaginal lavage before every immunisation and 3 weeks after the ﬁnal immunisation. (E) CN54 gp140
IgA and IgG ASC were measured by B-cell ELISPOT in spleens from mice 3 weeks after the ﬁnal immunisation. Antigen-speciﬁc T-cell proliferation
of splenocytes was assessed after in vitro stimulation with gp140 after 120h using (F)
3H-thymidine and (G) CFSE dilution. Data are shown as mean
of n55mice1SD, experiment was performed once. po0.05, po0.01, po0.001, one-way analysis of variance (ANOVA) with Tukey’s multiple
comparison post test.
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plus TSLP failed to induce any detectable response (mucosal or
systemic). However, we have shown that immunisation via the
vaginal route in mouse requires a systemic prime [42].
Here, we show for the ﬁrst time that TSLP has the capacity to
act as a mucosal adjuvant-inducing antibody and cellular
responses to gp140. This suggests that the role of TSLP in
promoting aberrant and protective immune responses is likely to
be both context and antigen speciﬁc [26]. Thus, the potential role
of TSLP in induction of protective mucosal responses to mucosal
pathogens, and to gp140 in particular, may offer important
insight to the induction of natural and/or vaccine mediated
mucosal immunity.
Materials and methods
Adjuvants
Carrier-free recombinant mouse TSLP and BAFF were purchased
from R&D systems (USA) and APRIL was purchased from PeproTech
(USA). CT from Vibrio cholerae was purchased from Sigma-Aldrich
(UK). Cytokines had no detectable levels of endotoxin, testing of
s a m p l e sb yL o n z a ,B a s e l ,S w i t z e r l a n d .B i o a c t i v i t yo fB A F Fa n dA P R I L
was tested on primary murine splenocytes.
Antigen
Trimeric recombinant gp140 (gp120 plus the external domain of
gp140) envelope protein from the HIV-1 clade C strain CN54 was
produced as a recombinant product in CHO cells and manufac-
tured to GMP speciﬁcation by Polymun Scientiﬁc, Vienna,
Austria. The clade C HIV-1 envelope clone p97CN54 was
originally isolated from a Chinese patient [43] and was made
available by H. Wolf and R. Wagner, University of Regensburg,
Germany.
Vaccine preparation and immunisation of mice
Female BALB/c mice were obtained from Harlan Olac (Epsom,
UK) and used when 6- to 10-weeks old. All work was performed
according to the Institutional and Home Ofﬁce guidelines. Ten
micrograms HIV-1 gp140 were mixed with PBS alone or in the
presence of 5mg TSLP, APRIL, BAFF or CT.
The ﬁnal volume in PBS for i.n. and i.d. administration was 20
and 50mL, respectively. For i.n. immunisation, mice were sedated
using isoﬂurane and 10mL of vaccination preparation was slowly
applied to each nostril using a micropipette.
For the airway challenge model, mice were immunised twice
at 2-week intervals, followed by three i.n. challenges at daily
intervals with 20mg gp140 in 100mL and were culled 3 days later
(Fig. 3D).
Sample collection and processing
Samples were obtained at pre-immunisation and 21 days after
each immunisation.
Blood/sera.
Blood was collected by tail bleeding and at the end of the
experiment by cardiac puncture. Sera were collected from
centrifuged, coagulated blood.
Vaginal samples.
Samples were collected by gentle washing of the vaginal mucosa
with 25mL of PBS. This procedure was repeated three times after
which the washes were pooled and placed on ice for 30min in the
presence of 5mlo f2 5  protease inhibitor cocktail (Roche
Diagnostics, Germany). After incubation, the samples were spun
at 13000g for 10min, the supernatants were collected and
stored at 801C until further use.
Faecal samples.
Ten faecal pellets were mixed with 400mL PBS11 protease
inhibitor cocktail per 100mg faeces, homogenised by vortexing,
and incubated for 1h on ice. The samples were centrifuged twice
at 13000g for 10min, the supernatants were collected and
stored at 801C.
Nasal lavage.
Nasal samples were obtained at the end of the experiment by
ﬂushing the nasal passage with 300mL of PBS11 protease
inhibitor cocktail and stored at 801C.
BAL.
BAL samples were collected and processed as described
previously [44]. Cells were enumerated by haemocytometer and
differential cell counts performed using H&E-stained cytospins.
Lungs for ﬁxation.
Histology samples were processed from 4%-formalin-ﬁxed lungs
and stained with hematoxylin and eosin (H&E), and mucus-
producing goblet cells were detected using PAS.
Splenocytes.
Splenocytes were isolated by mechanical dissociation through
sterile nylon mesh, followed by red blood cell lysis. Cells were
always kept on ice unless speciﬁed otherwise.
Detection of antigen-speciﬁc antibody responses by
ELISA
MaxiSorp 96-well plates were coated overnight with 5.0mg/mL
HIV-1 gp140 in PBS. Plates were blocked for 1h at 371C with
1% BSA in PBS. Serially diluted samples were incubated for 1h at
371C. Bound IgA and IgG was detected by incubation for 1h at
371C with horseradish peroxidase (HRP)-conjugated goat anti-
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conjugated goat anti-mouse IgA and IgE (AbD Serotec, UK). For
IgA and IgE detection, plates were incubated with Streptavidin-
HRP (R&D Systems) for 1h at 371C. Plates were developed using
tetramethylbenzidine (TMB) substrate. The reaction was stopped
with stop solution (1N H2SO4) and read at 450nm. Reciprocal
endpoint titres were calculated by using the GraphPad Prism 4
using a cut-off value at OD450 of 0.1 for IgG and serum and
vaginal IgA, and 0.5 for faecal IgA.
Ex vivo T-cell proliferation assays
Splenocytes were cultured in the presence of 5mg/mL gp140 for
120h. Concanavalin A (Con-A from Canavalia ensiformis, Sigma-
Aldrich) was used at 5mg/mL as a positive control of stimulation,
and medium alone as a negative control. The T-cell proliferation
response was measured by [
3H] thymidine incorporation into the
DNA or CFSE staining.
3H-thymidine.
0.5mCi [
3H] thymidine (GE Healthcare, UK) was added per well
16–18h before the end of the experiment. Plates were harvested
using a Harvester 96 (TOMTEC) and the counts per min (c.p.m.)
were counted in a 1450 Microbeta Plus Counter (Wallac Oy,
Finland). The T-cell proliferation response was expressed as the
stimulation index, which was calculated by dividing the experi-
mental c.p.m. (HIV-1 gp140) with the background c.p.m.
(medium). A stimulation index Z3 was considered as a positive
proliferation response.
CFSE.
One million cells were stained with 2mM CFSE at time zero,
according to manufacturers’ recommendations (CellTrace
TM
CFSE Cell Proliferation Kit, Invitrogen). After incubation with
antigen, the cells were stained with APC-H7-anti-CD8, Allophy-
cocyanin-anti-CD4 and PE-Cy5-anti-CD3 (BD) in addition to
staining with CFSE. Cell viability was assessed with the LIVE/
DEAD
s Fixable Violet Dead Cell Stain Kit (Invitrogen). Data
acquisition was performed using a FACS CANTO II cytometer (BD
Biosciences, San Jose, CA, USA), and the data analysed using the
FACS DIVA software version 6.1.3 (BD Biosciences).
Intracellular cytokine staining
Cells were stimulated for 6h with a peptide pool consisting of
39 peptides and 2mg/mL CD28 (BD Pharmigen), 50ng/mL
PMA and 500ng ionomycin (Sigma) or medium alone. Peptides
were selected from a bigger pool of 156 peptides covering the
whole of HIV-1 CN54 gp140 for their ability to restimulate
splenocytes in vitro after immunisation. Protein transport
inhibitor (containing Monensin, PB GolgiStop) was added at
the beginning of stimulation for peptides and medium alone and
2h later for PMA and ionomycin stimulation. Cells where labelled
for surface antigens using Paciﬁc Blue anti-mouse CD3e
(BD Pharmingen), V500 anti-mouse CD4 (BD Horizon), PerCP
anti-mouse CD8a (BioLegend) and blocked using puriﬁed rat
anti-mouse CD16/CD32 (Fc Block, BD Pharmingen). After
staining, cells where washed, ﬁxed and permeabilised using BD
Fixation/Permeabilisation Kit. Intracellular cytokine staining was
accomplished using PE-Cy7 anti-mouse IL-4, PE anti-mouse
IL-17A, allophycocyanin-Cy7 anti-mouse IL-2 (all BD Pharmin-
gen), FITC anti-mouse TNF-a and allophycocyanin anti-mouse
IFN-g (BioLegend). Appropriate isotype controls were used in all
steps. Staining speciﬁcity was conﬁrmed using ﬂuorescence
minus one (all Abs minus one). Analysis were performed onto a
FACS CANTO II cytometer, using FACS DIVA software (BD
Biosciences).
B-cell-ELISPOT
HIV-1 gp140 IgA-or IgG-speciﬁc B-cell-ELISPOT using ELISpot
PLUS for mouse IgA and IgG following manufacturers’ recom-
mendations (MABTECH, Sweden). For HIV-1 gp140-speciﬁc
responses, plates were coated overnight with 20mg gp140/mL
in PBS. Splenocytes were pre-cultured for 3 days with 5mg lectin
from Phytolacca americana (pokeweed) (Sigma) and 10ng
recombinant mouse IL-2 (R&D systems) prior to overnight
incubation on the coated ELISPOT plates prior to development.
Statistical analysis
Analyses were performed using the GraphPad Prism, version 4.00
(GraphPad Software). Statistical differences between groups
were calculated using one-way analysis of variance (ANOVA)
with appropriate post tests to measure signiﬁcance between pairs
of groups.
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